English | 中文版 | 手機(jī)版 企業(yè)登錄 | 個人登錄 | 郵件訂閱
當(dāng)前位置 > 首頁 > 行業(yè)資訊 > 展會 > 第二屆廣州核酸國際論壇 議程盛大公布

第二屆廣州核酸國際論壇 議程盛大公布

瀏覽次數(shù):2975 發(fā)布日期:2014-10-11  來源:本站 本站原創(chuàng),轉(zhuǎn)載請注明出處
主題:Nucleic Acids Translational Research & Therapeutics (siRNA, miRNA, lncRNA, antisense, CRISPR)
 
第二屆廣州核酸國際論壇(CNAF)以核酸轉(zhuǎn)化研究與治療為主題,旨在推動核酸研究和治療藥物的發(fā)展,加強(qiáng)中國與國際的交流合作,促進(jìn)中國核酸生物產(chǎn)業(yè)的進(jìn)步,展望核酸技術(shù)作為創(chuàng)新藥物第三大發(fā)展引擎的美好前景。
 
本屆論壇特邀20多位國際頂級科學(xué)家和企業(yè)家參會演講,嘉賓囊括諾貝爾獎得主、世界百強(qiáng)藥企的高級主管、世界頂級學(xué)府的著名教授、核酸制藥上市公司的總裁、核酸治療世界聯(lián)盟主席等,內(nèi)容涵蓋RNAi、microRNA、lncRNA、antisense、mRNA、exon-skipping、CRISPR等核酸技術(shù)最新進(jìn)展,包括從核酸基礎(chǔ)研究到產(chǎn)業(yè)化,從臨床前開發(fā)到臨床研究,并分享去年世界首個核酸藥物成功上市的經(jīng)驗。論壇的召開,將為國內(nèi)科學(xué)家及研究生提供與本領(lǐng)域?qū)W術(shù)權(quán)威面對面交流的難得機(jī)會,為國內(nèi)從事生物制藥的企業(yè)單位提供與世界知名藥企建立合作的紐帶。
 
我們期待與您相聚美麗羊城,共同迎接核酸治療時代的來臨!
 
主辦單位:專家聯(lián)誼會生物醫(yī)藥和生命科學(xué)專業(yè)委員會
中國生化與分子生物學(xué)會核糖核酸專業(yè)委員會
中國科學(xué)院廣州生物醫(yī)藥與健康研究院
中山大學(xué)
 
承辦單位:廣州市銳博生物科技有限公司
 
開幕主旨演講
Craig Mello教授
美國麻省大學(xué)醫(yī)學(xué)院教授
2006年諾貝爾生理學(xué)或醫(yī)學(xué)獎獲得者
 
主旨演講
Troels Koch博士
丹麥Santaris / Roche制藥公司首席技術(shù)官,研發(fā)副總裁
 
Ekkehard Leberer教授
法國賽諾菲研發(fā)聯(lián)盟管理高級總監(jiān), IMI COMPACT Consortium常務(wù)董事
 Muthiah Manoharan博士
美國Alnylam制藥公司高級副總裁,新藥開發(fā)負(fù)責(zé)人
Brett Monia博士
美國Isis 制藥公司高級副總裁
Oligonucleotide Therapeutics Society當(dāng)選主席
大會擬定議程
 
Wed, Nov 5, 2014
Registration  13:00-18:00
 
Thu, Nov 06, 2014 (Day 1)
 
Chair
Mano Manoharan, PhD  Senior Vice President, Alnylam Pharmaceuticals, USA
08:30-08:45
Introduction
CNAF Organizing Committee
08:45-09:30
Opening Keynote
Craig Mello, PhD  Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
Title:  RNA-guided genome defense and new frontiers in biotech and medicine
09:30-10:10
Keynote
Brett Monia, PhD  Senior Vice President, Isis Pharmaceuticals, OTS President, USA
Title: Transforming drug discovery for human therapeutics with antisense technology
10:10-10:35
Plenary
Judy Lieberman, MD, PhD  Professor, Program Chair, Harvard Medical School, USA
Title: Targeted gene knockdown to treat cancer
10:35-10:55
Tea Break
 
10:55-11:20
Plenary
Matthew Porteus, MD, PhD  Professor, Stanford School of Medicine, CRISPR Therapeutics Founder, USA
Title: Genome editing using engineered nucleases
11:20-11:45
Plenary
Erwei Song, MD, PhD  Professor and Vice Dean, Sun Yat-Sen Memorial Hospital, China
Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10
11:45-12:00
Technology
Rick Hogrefe, PhD  Founder, President and Chief Executive Officer, TriLink BioTechnologies
Title: Designing a mRNA therapeutic suitable for scale up
12:00-13:30
Lunch
 
13:30-13:35
Chair
Brett Monia, PhD  Senior Vice President, Isis Pharmaceuticals, OTS President, USA
13:35-14:15
Keynote
Troels Koch, PhD  Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
Title: LNA antisense – concepts & status
14:15-14:40
Plenary
Dmitry Samarsky, PhD  Executive Vice President, Technology Development, RiboBio, China
Title: In vivo delivery of therapeutic oligonucleotides and potential applications for cancer
14:40-15:05
Plenary
Georg Sczakiel, PhD  Professor, University of Lübeck, Germany
Title: Target RNA is involved in guide strand loading of Argonaute-2 and siRNA-induced RNA interference
15:05-15:25
Tea Break
 
15:25-15:50
Plenary
Peixuan Guo, PhD  Professor, William S. Farish Fund Endowed Chair, University of Kentucky, USA
Title: A new generation of drugs from the emerging field of RNA nanotechnology
15:50-16:15
Plenary
Yi Jin, PhD  Executive Vice President, Suzhou Ribo Life Science, China
Title: RNAi based therapeutics for Hepatitis B
16:15-16:30
Technology
Suresh Srivastava, PhD  Founder and President, ChemGenes, USA
Title: BMEG oligonucleotides for efficient cellular delivery for therapeutic and molecular biological applications
16:30-16:55
Plenary
David Lewis, PhD  Chief Scientific Officer, Arrowhead Research Corporation, USA
Title: Using Dynamic Polyconjugate® (DPC) technology to advance RNAi-based therapeutics
16:55-17:00
Day End
CNAF Organizing Committee
Fri, Nov 07, 2014 (Day 2)
09:00-09:05
Chair
Troels Koch, PhD  Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark
09:05-09:45
Keynote
Ekkehard Leberer, PhD  Professor, Senior Director of R&D Alliance Management, Sanofi, Germany
Title: Nucleic acid therapeutics: opportunities and challenges for innovation in drug development
09:45-10:10
Plenary
William Marshall, PhD  President and Chief Executive Officer, Board Director, miRagen Therapeutics, USA
Title: Discovery and development of microRNA targeting therapeutics
10:10-10:35
Plenary
Micky Tortorella, PhD  Chief Technology Officer and Vice President for Drug Discovery and Technology Transfer, Guangzhou Institutes of Biomedicine and Health, China
Title: Intra-articular delivery of siRNA-conjugates as new disease modifying osteoarthritis drugs
10:35-10:55
Tea Break
 
10:55-11:20
Plenary
Chengyu Jiang, PhD  Professor, Chair, Peking Union Medical College, CAMS, China
Title: Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro
11:20-11:45
Plenary
Marc Lemaitre, PhD  Chief Executive Officer, Sirnaomics, USA / China
Title: Improving siRNA therapeutics using polymer-nanoparticle (PNP) delivery: recent pre-clinical results with STP705 against skin scars
11:45-12:00
Technology
Kimo Sanderson  Vice President, Asahi Kasei, Japan
Title: Therapeutic oligonucleotides from discovery to development: the importance of proper production and scale up
12:00-13:30
Lunch
 
13:30-13:35
Chair
William Marshall, PhD  President, Chief Executive Officer, Board Director, miRagen Therapeutics, USA
13:35-14:15
Keynote
Mano Manoharan, PhD  Senior Vice President, Alnylam Pharmaceuticals, USA
Title: Chemical strategies for systemic delivery of RNAi drugs
14:15-14:40
Plenary
Dirk Haussecker, PhD  Founder and Curator, RNAi Therapeutics Blog, Germany
Title: RNA therapeutics emerging as major drug discovery engine
14:40-15:05
Plenary
TBD
15:05-15:20
Technology
Carina Andersson, PhD  Marketing Head, GE, USA
Title: A manufacturing solution of oligonucleotides
15:20-15:40
Tea Break
 
15:40-16:05
Plenary
Sven Klussmann, PhD  Chief Scientific Officer, NOXXON Pharma, Germany
Title: From bench to bedside – the conversion of mirror-image oligonucleotides into therapeutics
16:05-16:30
Plenary
Ryszard Kole, PhD  Distinguished Scientist, Professor, Sarepta Therapeutics, USA
Title: Eteplirsen, a phosphorodiamidate morpholino oligonucleotide, as treatment for Duchenne muscular dystrophy (DMD)
16:30-16:55
Plenary
René Thürmer, PhD  Deputy Head of the Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany
Title: Regulatory aspects of nucleic acids therapeutics
16:55-17:15
Closing Remarks
Craig Mello, PhD  Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA
 
會議時間:2014年11月5-7日
會議地點:廣州科學(xué)城翡翠皇冠假日酒店
會議語言:英語
論壇網(wǎng)站:www.cnaf.org.cn點此注冊
 
贊助企業(yè)
 
白金贊助
金牌贊助
銀牌贊助
 
 
 
 
 
銅牌贊助
 
專項贊助
 
聯(lián)系我們:

贊助咨詢:
楊先生 
電  話:(020)32290221-641; 18933996781
郵  箱:
sponsorship@cnaf.org.cn

注冊及其他咨詢:
官小姐
電話:
020)32290221-656
郵箱:
register@cnaf.org.cn ; info@cnaf.org.cn

                                                      



用戶名: 密碼: 匿名 快速注冊 忘記密碼
評論只代表網(wǎng)友觀點,不代表本站觀點。 請輸入驗證碼: 8795
Copyright(C) 1998-2024 生物器材網(wǎng) 電話:021-64166852;13621656896 E-mail:info@bio-equip.com